Aerie Pharma (AERI) Receives a Buy from Oppenheimer


In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on Aerie Pharma (AERI), with a price target of $28.00. The company’s shares closed last Monday at $19.89, close to its 52-week low of $17.15.

According to TipRanks.com, Rajavelu is a 3-star analyst with an average return of 1.3% and a 52.9% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Teva Pharmaceutical Industries, and Arrowhead Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $39.00 average price target, representing a 101.2% upside. In a report issued on February 7, Mizuho Securities also assigned a Buy rating to the stock with a $54.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $50.10 and a one-year low of $17.15. Currently, Aerie Pharma has an average volume of 798.2K.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AERI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts